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ABSTRACT: The Staphylococcus aureus multidrug binding protein QacR binds to a broad spectrum of
structurally dissimilar cationic, lipophilic drugs. Our previous structural analyses suggested that ﬁve QacR
glutamic acid residues are critical for charge neutralization and speciﬁcation of certain drugs. For example,
E57 and E58 interact with berberine and with one of the positively charged moieties of the bivalent drug
dequalinium. Here we report the structural and biochemical effects of substituting E57 and E58 with
alanine and glutamine. Unexpectedly, individual substitutions of these residues did not signiﬁcantly affect
QacR drug binding afﬁnity. Structures of QacR(E57Q) and QacR(E58Q) bound to dequalinium indicated
that E57 and E58 are redundant for charge neutralization. The most signiﬁcant ﬁnding was that berberine
was reoriented in the QacR multidrug binding pocket so that its positive charge was neutralized by side
chain oxygen atoms and aromatic residues. Together, these data emphasize the remarkable versatility of
the QacR multidrug binding pocket, illustrating that the capacity of QacR to bind myriad cationic drugs
is largely governed by the presence in the pocket of a redundancy of polar, charged, and aromatic residues
that are capable of electrostatic neutralization.
Multidrug resistant bacteria represent a major global health
threat that has in great part arisen through the action of
multidrug efﬂux transporters. Capable of transporting a broad
range of structurally and chemically diverse compounds from
the cell, these proteins afford simultaneous resistance to
multiple cytotoxic compounds and drugs. Despite this
apparent promiscuity in substrate binding, each multidrug
binding protein binds to a precise array of compounds.
Uncovering the determinants that deﬁne this speciﬁcity in
polyspeciﬁc substrate recognition may provide the key to
combating multidrug resistance.
Important insights into multidrug recognition have been
gained by examining the soluble regulatory proteins of
bacterial multidrug efﬂux transporters, which are more
amenable to high-resolution structural analyses and bind to
many of the same compounds that are substrates for the
pumps that they regulate. One such protein is QacR, the
transcriptional repressor of the Staphylococcus aureus mul-
tidrug resistance efﬂux gene qacA. QacR is a member of
the TetR family of repressors which share a helix-turn-helix
DNA binding motif at their N-terminal regions but encode
diverse C-terminal domains that are utilized in binding
protein-speciﬁc inducing compounds (1–3). QacR binds to
the IR1 DNA operator sequence, a large inverted repeat that
overlaps the qacA promoter, as a pair of dimers (4, 5) and is
induced by numerous structurally dissimilar, monovalent and
bivalent cationic, lipophilic compounds (6, 7). Drugs bind
to QacR in a one drug:QacR dimer stoichiometry (8),
inducing a coil-to-helix transition of residues 89-93 within
the drug-bound subunit of the dimer. Residues Y92 and Y93
are consequently expelled from the interior of the protein,
leading to the formation of a large binding pocket (8). This
conformational switch also leads to the relocation of the DNA
binding domains, rendering the protein unable to bind the
IR1 operator site, thus allowing upregulation of qacA
transcription (8).
The QacR multidrug binding pocket created by this
conformational switch is expansive and has been described
as containing two distinct but partially overlapping binding
sites, designated the rhodamine 6G (R6G)
1 and ethidium (Et)
sites after their respectively bound drugs. This pocket
contains ﬁve glutamate, multiple aromatic and nonpolar, and
several polar residues that mediate drug interactions (8). The
majority of the drugs, including the monovalent plant alkaloid
berberine (Be), bind in the R6G site. However, the binding
of drugs is not restricted solely to the R6G or Et sites. For
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residues categorized to be within both sites, including the
acidic residues E90 and E120, by binding in an intermediary
region. The multifaceted nature of the QacR drug binding
pocket also explains how it is able to bind bivalent drugs as
exempliﬁed by the structure of QacR bound to dequalinium
(Dq). In this structure, each of the two positively charged
aminomethylquinolinium moieties of Dq, which are con-
nected by a 10-methylene carbon linker, inserts into one of
the canonical sites, i.e., one into the R6G site and the other
into the Et site (8). Notably, although each drug utilizes a
different subset of QacR residues for binding, all, with the
exception of pentamidine (Pt), which is complemented by
residue E63, π-π, cation-π, and dipole-charge interac-
tions, contact one or more of the four glutamate residues at
positions 57, 58, 90, and 120 (8). The utilization of cation-π
interactions has also been observed in the interaction of other
multidrug binding proteins with drugs, most notably that of
the RND-type multidrug transporter AcrB from Escherichia
coli (9, 10). Indeed, structures of AcrB bound to several drugs
have highlighted the importance of cation-π and stacking
interactions in the polyspeciﬁc binding of its ligands (10).
While cation-π and stacking interactions appear to be
important in multidrug binding, several studies suggest that
negatively charged residues are likely to play a primary role
in their recognition (11). This proposition has been supported
by several biochemical studies involving the mutational
analysis of acidic residues such as those described for the
BmrR multidrug binding transcriptional regulator in Bacillus
subtilis (11) and the multidrug resistance transport proteins
MdfAandEmrEinE.coli(12,13),QacAinS.aureus(14,15),
and human MRP1 (16). However, the relative contribution
of each of the glutamate residues to the binding of different
drugs in the QacR multidrug binding pocket is unclear.
To begin to address the role(s) of negatively charged
residues in the multidrug binding pocket of QacR, we
analyzed the effect of mutating two key acidic residues, E57
and E58, to alanine and glutamine on drug binding by QacR.
Three drugs, Dq, Be, and MG, were assayed for their ability
to bind these mutant proteins. These compounds were chosen
because it was anticipated that their binding would be
affected differently by these mutations. Speciﬁcally, since
one of the two positively charged moieties of Dq interacts
with residues E57 and E58, their substitution would be
predicted to manifest some but not a drastic change in drug
binding (8). On the other hand, residues E57 and E58 appear
to provide the sole neutralization for the positive charge of
Be, suggesting that mutating these residues is likely to affect
its binding signiﬁcantly (8). By contrast, MG makes no
contacts with these residues, and thus, the binding of this
aromatic monovalent cation to QacR would be predicted to
be altered little, if any, by such mutations (8). In other words,
MG served as a control, and it was expected that it would
bind like the wild type (wt) to these mutant QacR proteins.
In addition to the binding afﬁnities of QacR(E57A/Q) and
QacR(E58A/Q) for Be, Dq, and MG, the crystal structures
of the QacR(E57Q)-Dq, QacR(E57Q)-MG, QacR(E58Q)-
Be, QacR(E58Q)-Dq, and QacR(E58Q)-MG complexes
were determined. The resulting data reveal unanticipated
complexity in QacR multidrug binding and point to chemical
redundancy as a key underlying principal of the ligand
polyspeciﬁcity of this and likely other multidrug binding
transcription regulators and efﬂux transporters.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions. All cloning and
overexpression procedures were performed in E. coli strain
DH5R (17). This strain was transformed by standard
procedures and cultured at 37 °C in Luria-Bertani broth or
agar (17) containing, where appropriate, 100 µg/mL ampicillin.
DNA Isolation and Manipulations. The Quantum Prep
plasmid miniprep kit (Bio-Rad) was employed to isolate
plasmid DNA from E. coli. Restriction enzymes, T4 DNA
ligase, calf intestinal alkaline phosphatase, and Taq DNA
polymerase (all from New England Biolabs), were each used
according to the manufacturer’s instructions. Oligonucle-
otides were purchased from GeneWorks. PCR products were
puriﬁed with the Wizard PCR Prep kit (Promega), and DNA
fragments were isolated from agarose gels using the GFX
PCR and gel band puriﬁcation kit (Amersham Biosciences).
Construction of QacR Mutants. The single QacR mutants
E57A, E57Q, E58A, and E58Q and the double QacR mutant
variant E57Q/E58Q were obtained by generating a PCR-
derived fragment encompassing the residue to be mutated
and replacing the wt sequence. This was achieved by
subcloning into the pTTQ18-based qacR clone pSK5676 (7),
which has a six-histidine tag incorporated into the C-terminus
of the expressed QacR protein. Automated DNA sequencing,
performed at the Australian Genome Research Facility
(Brisbane, Australia), was employed to verify the presence
of the desired mutations and the absence of spurious
mutations that may have been introduced during PCR.
Protein Puriﬁcation. Mutant QacR proteins were overex-
pressed from cells carrying plasmid derivatives of pSK5676,
puriﬁed by Ni2+-NTA metal chelate afﬁnity chromatography
(Invitrogen ProBond resin), and dialyzed against buffer A
[1 M NaCl, 20 mM Tris-HCl, and 5% (v/v) glycerol (pH
7.5)] as previously described (7). The puriﬁed proteins were
more than 99% pure as estimated from Coomassie-stained
SDS-PAGE gels, and their concentrations were determined
using the Coomassie plus protein assay reagent (Pierce).
Tryptophan Fluorescence Measurements. Fluorescence
intensity measurements of QacR proteins were performed
and Kd values calculated as described previously (7) with
the exception that ligand stocks (2.5 mM) were dissolved in
Milli-Q water and dilutions made as required in buffer B
[100 mM NaCl, 15 mM Tris-HCl, and 2.5% (v/v) glycerol
(pH 7.5)]. Each of the reported Kd values represents an
average of three independent experiments (Figure S1).
Intrinsic ﬂuorescence could not be used to assess QacR
binding to Dq because Dq displays signiﬁcant ﬂuorescence
at 340 nm, and therefore, Dq binding was assessed by
isothermal titration calorimetry.
Isothermal Titration Calorimetry. Isothermal titration
calorimetry (ITC) was used to determine the afﬁnity of QacR
proteins for Dq and carried out as described previously (18)
(see ref 18 and Figure S2). Dq was dissolved in buffer B,
and ligand and protein concentrations were determined
spectrophotometrically. Protein and ligand samples were
degassed before being loaded into the cell and syringe of
the VP-ITC from MicroCal Inc. (Northampton, MA) at
concentrations of 8 and 280 µM, respectively. The stirring
Redundancy of QacR Multidrug Cation Neutralization Biochemistry, Vol. 47, No. 31, 2008 8123speed was set to 300 rpm and the power to 10 µcal/s, and
the experimental data were collected at 23 °C. Data analyses
were performed with Origin 5.0 (MicroCal Inc.).
Crystallization, Data Collection, and Structure Determi-
nation of Mutant QacR-Drug Complexes. Puriﬁed QacR
mutant proteins were subjected to reductive alkylation of
lysines, which allows reproducible crystallization of QacR-
drug complexes (8, 19). The reductive alkylation was
terminated by the addition of 200 mM glycine. The resulting
alkylated proteins were concentrated to 10-15 mg/mL,
during which the protein was buffer exchanged into a solution
of 50 mM Tris (pH 7.5), 50 mM imidazole, 300 mM NaCl,
and 5% glycerol. Reductive alkylation of QacR has been
demonstrated to have no detrimental effect on its ability to
bind drugs (8). QacR complexes were crystallized at room
temperature using the hanging drop vapor diffusion method.
QacR(E57Q)-MG, QacR(E58Q)-MG, and QacR(E58Q)-Be
complexes were produced via addition of drug to the protein
solution to ﬁnal concentrations ranging from 100 to 200 µM
and overnight incubation. Because Dq displays low solubility,
QacR(E57Q)-Dq and QacR(E58Q)-Dq complexes were
formed via addition of a small amount of solid Dq to the
protein solution and incubation for several hours at 4 °C.
The mixture was then centrifuged, and the supernatant, which
contained the QacR-Dq complex, was used for crystalliza-
tion. Each QacR-drug complex was mixed 1:1 with the
crystallization solution of 2.9 M ammonium sulfate and
50-150 mM sodium acetate (pH 4.6) and sealed over a 1
mL reservoir of the same solution. Data-quality crystals were
obtained for the QacR(E57Q)-Dq, QacR(E57Q)-MG,
QacR(E58Q)-Dq, QacR(E58Q)-MG, and QacR(E58Q)-Be
complexes. Despite numerous attempts, the QacR(E57Q)-Be
and QacR(E57Q/E58Q)-drug complexes did not crystallize
or data-quality crystals could not be obtained. X-ray intensity
data were collected at 100 K at ALS beamline 4.2.2 and the
data processed with MOSFLM and scaled with SCALA
(20, 21). All crystals took the native P42212 space group.
However, because of slight changes in the cell edges of the
mutant structures compared to those of the wild type, the
wt coordinates were optimally positioned into the new unit
cells using the molecular replacement program MOLREP
as implemented in CCP4. The structures were reﬁned in CNS
(22). O was utilized to visualize experimental electron density
maps and for model building (23). Each structure was
validated with PROCHECK (24). Table 1 lists selected data
collection and reﬁnement statistics for each of the complexes.
Figure 1 was made with PyMol (25), while Figures 4–6 were
made with Chimera (26). The atomic coordinates and
structure factors for each structure have been deposited in
theProteinDataBankasentries3BT9fortheQacR(E57Q)-Dq
complex, 3BTC for the QacR(E57Q)-MG complex, 3BTI
for the QacR(E58Q)-Be complex, 3BTJ for the QacR-
Table 1: Selected Data Collection and Reﬁnement Statistics
QacR(E57Q)-Dq QacR(E57Q)-MG QacR(E58Q)-Be QacR(E58Q)-Dq QacR(E58Q)-MG
space group P42212 P42212 P42212 P42212 P42212
unit cell constants (Å) a ) b ) 171.24 a ) b ) 171.44 a ) b ) 171.5 a ) b ) 171.9 a ) b ) 171.8
c ) 94.2 c ) 94.74 c ) 94.4 c ) 94.5 c ) 94.8
resolution (Å) 81.6-2.75 76.8-2.90 76.7-2.85 81.7-2.98 76.8-2.90
overall Rsym (%)
a 4.5/38.4 4.7/33.6 8.1/47.5 6.8/47.8 5.5/31.7
overall I/σ(I) 12.0/2.0 12.3/2.1 5.7/1.8 9.3/1.8 8.9/2.4
total no. of reﬂections 128283/7823 196681/14856 116739/16219 102268/12907 286661/12390
no. of unique reﬂections 36964/2617 31866/2200 33379/4779 29386/4125 31835/4561
completeness (%) 96.5/72.9 99.3/99.3 99.8/99.8 99.6/99.7 99.4/99.4
Reﬁnement Statistics
Rwork/Rfree (%)
b 23.9/29.0 24.0/28.8 21.7/27.5 21.2/26.4 22.2/26.4
root-mean-square deviation
bond angles (deg) 1.25 1.16 1.03 1.26 1.16
bond lengths (Å) 0.009 0.009 0.008 0.009 0.009
B-values (Å2) 1.6 1.5 1.6 1.7 2.5
Ramachandran analysis
most favored (%, no.) 87.1/610 88.4/616 87.1/610 86.4/605 87.1/610
additional allowed (%, no.) 11.6/81 10.0/70 11.7/82 12.0/84 11.6/81
generously allowed (%, no.) 0.6/4 0.9/6 0.4/3 0.9/6 0.6/4
disallowed (%, no.) 0.7/5 0.7/5 0.7/5 0.7/5 0.7/5
a Rsym ) ∑∑|Ihkl - Ihkl(j)|/∑NIhkl, where Ihkl(j) is the observed intensity and Ihkl is the ﬁnal average value of intensity.
b Rwork and Rfree ) ∑||Fobs| -
|Fcalc||/∑Fobs, where Fobs is the observed structure factor amplitude and Fcalc the calculated structure factor amplitude for the working and test sets,
respectively. Data for highest-resolution shells given after the slash.
FIGURE 1: Structure of the QacR(E58Q)-Be complex. A ribbon
diagram of QacR(E58Q) bound to berberine with the drug-bound
subunit colored yellow and the drug-free subunit gray. Secondary
structural elements and the N- and C-termini are labeled. Residues
E57 and E58 are shown as CPK. Berberine is shown as orange
sticks.
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(E58Q)-MG complex.
RESULTS
Structural analyses of QacR in complex with nine cationic
drugs (8, 27, 28) suggested that the formal negative charge
carried by glutamate residues that line the QacR multidrug
binding pocket is pivotal in their neutralization and, thus, to
binding afﬁnity of these positively charged drugs. Here we
examined the effect of substituting glutamate residues E57
and E58, which lie proximal to the positively charged
nitrogen atoms of the bound drugs Be and Dq but are distal
to the positive charge of MG (8), with the uncharged residues
alanine and glutamine (Figure 1). The double glutamine
substitution, QacR(E57Q/E58Q), was also constructed and
examined. Drug binding afﬁnities of mutant proteins were
determined, and structures of QacR(E58Q) bound to Be, Dq,
and MG and QacR(E57Q) bound to Dq and MG were
determined.
Drug Binding Afﬁnities. Utilizing the intrinsic ﬂuorescence
quenching of tryptophan residues, the binding afﬁnities of
wt and mutant QacR proteins were determined for MG and
Be. Because Dq exhibited signiﬁcant ﬂuorescence at 340 nm,
ITC was used to obtain the binding afﬁnities for this
compound. As predicted, there was no signiﬁcant difference
between the binding afﬁnities of mutant QacR proteins for
MG compared to wt QacR, with changes not exceeding 2.4-
fold (Table 2). However, unexpectedly, this was also true
for the majority of the QacR mutants with Be and Dq; i.e.,
nearly all displayed binding afﬁnities for these drugs within
2-fold of that of wt QacR (Table 2). The notable exceptions
were QacR(E58Q) and the double mutant QacR(E57Q/
E58Q), which remarkably displayed a 4- and 9-fold increases
in afﬁnity for Be, respectively. By contrast, the QacR(E57Q/
E58Q) double mutant exhibited a 4-fold decrease in binding
afﬁnity for Dq (Table 2).
Structural Determination of QacR(E57Q)- and (E58Q)-
Drug Complexes. To understand the molecular basis for the
unexpecteddrugbindingafﬁnitiesexhibitedbytheQacR(E57Q)
and QacR(E58Q) mutants, we conducted X-ray crystal-
lographic experiments with these QacR mutants in complexes
with Be, Dq, and MG. Crystal structures were obtained for
QacR(E57Q) bound to Dq or MG and for QacR(E58Q) in
complex with Be, Dq, or MG. Structures of QacR(E57Q)
bound to MG and Dq were reﬁned to ﬁnal Rwork and Rfree
values of 24.0 and 28.8% to 2.90 Å resolution and 23.9 and
29.0% to 2.75 Å resolution, respectively. Structures of
QacR(E58Q) bound to Be, MG, and Dq had Rwork and Rfree
values of 21.7 and 27.5%, 22.2 and 26.4%, and 21.2 and
26.4% and were resolved to 2.85, 2.90, and 2.98 Å resolution,
respectively. Electron density for each drug was clear
(Figures 2a,b and 3a-c). Selected data collection statistics,
reﬁnement statistics, and the Ramachandran plot values of
each complex are given in Table 1. Consistent with the
crystallographic isomorphism of the mutant-drug complexes
and corresponding wt QacR-drug complexes, root-mean-
square deviations (rmsd) of <0.70 Å were obtained after
superimposition of all corresponding CR atoms, demonstrat-
ing that no global structural changes were produced by the
E57Q or E58Q substitution (Figures 1, 4, and 5).
Because E57 and E58 make no contacts with MG and their
mutations have little effect on drug binding, we predicted
that the structures of these mutants in complex with MG
would remain wt. Indeed, the binding site occupied by
MG in both the QacR(E57Q)-MG and QacR(E58Q)-MG
structures was found to be identical to that in the wt
QacR-MG structure with the same protein-drug interactions
being made (Figures 4b and 5c and Table 3). These included
contacts from QacR residues E90 and E120 to the two
dimethylamino groups of MG, at which the delocalized
positive charge largely rests. In addition, critical aromatic
contacts provided by QacR residues W61, Y93, Y103, Y123,
and F162′ (where the prime indicates the other subunit of
the dimer) were conserved between the mutant and wt
structures. In the QacR(E57Q)-Dq and QacR(E58Q)-Dq
structures, Dq was also bound essentially in the same manner
as in wt QacR, with the majority of the protein-drug contacts
maintained (Figures 4a and 5b and Table 3). Speciﬁcally,
Dq spanned the R6G and Et subpockets such that one
positively charged aminomethylquinolinium group remained
neutralized by E120 and the other largely by the unsubstituted
carboxylate of either E57 or E58. Thus, in the case of Dq,
there appears to be a functional redundancy of the charged
groups of residues E57 and E58 such that in the Dq structure
only one of these carboxylate side chains was necessary to
interact with, and thereby neutralize, the positively charged
aminomethylquinolinium group that was inserted into the
R6G pocket. In addition, W61 and Y93 also provide
cation-π interactions to aid in charge neutralization of this
aminomethylquinolinium group. This was consistent with
binding data showing that when both E57 and E58 were
changed to glutamine there was a reduction, albeit modest
(4-fold), in the level of QacR binding to Dq, while single
substitutions of each residue had no discernible effect on
the QacR-Dq binding afﬁnity or binding mode (Table 2).
By sharp contrast to the essentially wt modes of binding
of MG and Dq to QacR(E57Q) and QacR(E58Q), the mode
of binding of Be to QacR(E58Q) was quite different from
that observed in the wt QacR-Be complex (Figures 5a and
6 and Table 2). In the QacR(E58Q) structure, the Be
molecule occupied roughly the same position in the pocket
relative to its location in wt QacR; however, the drug was
FIGURE 2: Electron density maps (2Fo - Fc) of QacR(E57Q) in
complex with (a) malachite green (MG) and (b) dequalinium (Dq).
The molecules are shown as sticks with carbon, nitrogen, and
oxygen atoms colored yellow, blue, and red, respectively. The maps
were calculated after reﬁnement of the protein structure and prior
to addition of the drugs. The contour level is 0.8σ.
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In this new position, the delocalized positive charge, which
is centered on N1 of Be, moved 3 and 4 Å from residues 57
and 58, respectively, and was now located 3.8 Å from the
hydroxyl side chain of residue T89. Interestingly, this new
location placed the N1 atom of Be 2.5 Å closer to the
carboxylate side chain of E90 as compared to its wt QacR
position (new distance of ∼7 Å), conferring a new long-
range electrostatic interaction that may contribute to the
neutralization of the positive charge of the drug (Table 3).
However, charge neutralization of Be in this new orientation
was mediated primarily by aromatic and polar residues
(Figures 5a and 6b). These include more favorable stacking
interactions from the side chain of Y123. Indeed, the side
chain of residue Y123 was rotated in the mutant structure
from its wt conformation to make these interactions (Figures
5a and 6a,b). In addition to providing enhanced stacking
interactions, the rotation of the Y123 side chain was coupled
to the ﬂipped conformation of Be in the QacR(E58Q) protein
as the drug and Y123 side chain would clash if either
maintained its wt binding mode. In this new binding position,
Be was also able to make more favorable interactions with
the side chain of residue W61. Finally, in its new position,
the Be molecule makes van der Waals interactions with the
side chain of S68. These new and enhanced interactions
between Be and QacR(E58Q) are consistent with the
modestly improved binding afﬁnity of this mutant for Be
compared to wt QacR (Table 2).
DISCUSSION
The presence of charged residues in the ligand binding
pockets of multidrug binding proteins has emerged as an
important drug binding determinant. Indeed, substitution of
a key glutamate residue (E253) in the ligand binding pocket
of the C-terminal binding domain of the multidrug transcrip-
tion regulator, BmrR, resulted in the abolition of binding to
the majority of representative cationic co-activators (11). In
the S. aureus multidrug binding repressor protein QacR,
which binds to a diverse yet precise array of cationic
compounds, it was predicted that glutamate residues lining
the multidrug binding pocket would play a key role in drug
binding afﬁnity. Evidence supporting this prediction was
previously provided by crystallographic and binding analyses
of QacR binding simultaneously to the two drugs Et and
proﬂavine. These data indicated that disruption of the
interaction of Et with E120 signiﬁcantly reduced its binding
afﬁnity (28).
The QacR E57 and E58 residues were predicted from
earlier crystallographic studies to be important for drug
binding. These residues interact with one of the positively
charged aminomethylquinolinium moieties of the bivalent
FIGURE 3: Electron density maps (2Fo - Fc) of QacR(E58Q) in complex with (a) malachite green (MG), (b) dequalinium (Dq), and (c)
berberine (Be). The molecules are shown as sticks with carbon, nitrogen, and oxygen atoms colored yellow, blue, and red, respectively. The
maps were calculated after reﬁnement of the protein structure and prior to addition of the drugs. The contour level is 0.7σ.
FIGURE 4: Views of the multidrug binding pockets of superimposed wt QacR (light blue) and QacR(E57Q) (orange) in complex with (a)
dequalinium (Dq) and (b) malachite green (MG). For clarity, only key residues are shown. Nitrogen and oxygen atoms are colored dark
blue and red, respectively. Helices containing residues interacting with the drug are labeled.
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Be (8). In this study, we examined the effect of mutating
these residues to both alanine and the isosteric residue
glutamine, the side chains of which do not carry a formal
negative charge, on drug binding by QacR. Contrary to
expectations, our results demonstrated that the formal nega-
tive charge of the E57 and E58 side chains alone does not
contribute signiﬁcantly to drug binding afﬁnity (Table 2).
Noticeably, this near-isoenergetic drug binding displayed by
the QacR E57 and E58 mutants appears to be primarily
attributable to the functional and chemical redundancy of
residues that are capable of electrostatic neutralization in the
QacR multidrug binding pocket.
This mechanism was clearly evident in the structures
of QacR(E57Q) and QacR(E58Q) bound to Dq and
QacR(E58Q) bound to Be. In both the QacR(E57Q)-Dq
and QacR(E58Q)-Dq complex structures, movement of
Dq in the multidrug binding pocket was negligible (Figures
4a and 5b), with the immediate functional redundancy
provided by E57 and E58 in the R6G subpocket apparently
being sufﬁcient to permit the essentially isoenergetic
binding mode of Dq. Consistent with this, mutation of
FIGURE 5: Views of the multidrug binding pockets of superimposed
wt QacR (light blue) and QacR(E58Q) (yellow) in complex with
(a) berberine (Be), (b) dequalinium (Dq), and (c) malachite green
(MG). For clarity, only key residues are shown. Nitrogen and
oxygen atoms are colored dark blue and red, respectively. Helices
containing residues interacting with the drug are labeled.
FIGURE 6: Magniﬁcation of the multidrug binding pockets of
superimposed wt QacR (blue) and QacR(E58Q) (yellow) in complex
with berberine. Shown are two views related by an ∼90° rotation.
Note the striking reorientation of the drug in the E58Q mutant
protein and the altered location of the Y123 side chain in the mutant
structure.
Table 2: Effect of Substitutions of QacR Residues E57 and E58 on
Drug Binding Afﬁnity (Kd) in Vitro
compound (µM)
QacR MG
a Be
a Dq
a
wt 1.23 ( 0.14 2.86 ( 0.62 1.30 ( 0.30
E57A 2.98 ( 0.23 1.88 ( 0.23 ND
b
E57Q 1.77 ( 0.17 1.39 ( 0.15 1.95 ( 0.18
E58A 0.81 ( 0.19 1.35 ( 0.10 ND
b
E58Q 1.09 ( 0.07 0.72 ( 0.08 2.40 ( 0.20
E57Q/E58Q 1.99 ( 0.08 0.32 ( 0.15 5.20 ( 3.80
a Values represent an average of three separate experiments.
b Not
determined.
Table 3: Distances between Residues E57, E58, E90, and E120 and
Berberine (Be), Malachite Green (MG), and Dequalinium (Dq) in the wt
and QacR(E57Q) and QacR(E58Q) Mutant-Drug Complexes
a
distance (Å)
charge center QacR E/Q57 E/Q58 E90 E120
Be (N1) wt 5.6 4.9
E58Q 8.7 8.6
MG (N2) wt 3.4
E57Q 3.8
E58Q 3.5
MG (N3) wt 3.6
E57Q 4.3
E58Q 3.7
Dq (N1) wt 4.8
E57Q 4.4
E58Q 4.9
Dq (N2) wt 4.8 4.9
E57Q 4.3 5.9
E58Q 4.7 5.7
a The distances (in angstroms) are from the atom in the speciﬁed
residue that is closest to the listed atom in the drug.
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decrease in binding afﬁnity (Table 2). The fact that the
E57Q/E58Q double mutant displayed an only 4-fold
reduction in Dq binding afﬁnity is attributed in great part
to the retention of the E120-aminomethylquinolinium
interaction and the large number of contacts between QacR
and Dq in this preferred binding mode. Indeed, the large
size and extended nature of the Dq molecule appear to
constrain it to adopt only one conformation within the
pocket.
A more complex form of redundancy in the QacR
multidrug binding mechanism is observed in the QacR-
(E58Q)-Be structure. Strikingly, in this complex, Be
reorients in the multidrug binding pocket such that the
positive charge centered on N1 of Be is no longer im-
mediately complemented by either E57 or E58, or indeed
by any other acidic residue (Figures 5a and 6a,b). Moreover,
this new position allows Be to make more favorable stacking
interactions with the side chains of aromatic residues W61,
Y93, and Y123, thereby providing π-π and cation-π
complementation of the drug. In addition, the negative dipole
of the side chain oxygen atom of residue T89 makes a direct
contact with the N1 atom of Be, providing further charge
stabilization. These combined changes likely explain the
4-fold increase in binding afﬁnity of Be for the QacR(E58Q)
mutant compared to wt. A similar mechanism of drug
reorientation with alternative charge complementation and
enhanced contacts may explain the 9-fold increase in binding
afﬁnity for Be by the double mutant QacR(E57Q/E58Q)
(Table 2), the complex of which has failed to yield crystals.
Collectively, these data suggest that the involvement of
acidic residues E57 and E58 in the QacR multidrug binding
pocket is not absolutely required for the neutralization or
binding afﬁnity of either cationic drug Be or Dq. This is in
direct contrast to observations made regarding other multi-
drug binding proteins such as EmrE, MdfA, and BmrR, for
which acidic residues have been shown to directly mediate
a signiﬁcant energetic contribution to ligand binding (11–15).
Indeed, a recent study of the TetR-family multiligand binding
transcription repressor, TtgR, indicated that binding of
phloretin to the high-afﬁnity site of TtgR was dependent upon
its interaction with a speciﬁc arginine residue (29). Glycine
substitution of this residue destroyed binding to this site,
whereas notably, TtgR has a second “general” binding site
to which phloretin and other drugs bind with lower afﬁnity,
which is not dependent upon charged residues (29). Never-
theless, the unusual mode of Be neutralization by the
QacR(E58Q) mutant is somewhat similar to what has been
observed in the QacR-Pt complex (27). Like Dq, Pt is a
bivalent drug, and in the QacR-Pt structure, one of the
positively charged benzamidine moieties of Pt was neutral-
ized by the carboxylate side chain of residue E63 while the
other was electrostatically complemented not by glutamate
or aspartate residues, but by stacking and dipole-charge
interactions from residues S86, Y127, A153, and N157 (27).
Thus, the QacR(E57Q)-Be and QacR-Pt structures indicate
that aromatic residues can play a central role in drug
neutralization because they can complement both the lipo-
philic and charged nature of the drugs. Similar contacts are
thought to be important in the interactions of ligands and
multidrug efﬂux transport proteins Pgp and LmrA (30),
neither of which contains acidic residues within its trans-
membrane domain, but they both still selectively interact with
and export cationic compounds (31, 32). This contention is
supported by the ﬁnding that site-directed substitution of
aromatic residues in the transmembrane domain of Pgp had
a negative impact on transport activity and drug resistance
(33, 34). Additionally, structures of drug-bound AcrB have
revealed an aromatic rich binding pocket containing many
candidates for hydrophobic or π-π interactions (10).
One interpretation of these data is that the acidic residues
in the QacR multidrug binding pocket contribute primarily
to polyspeciﬁc binding capability and drug orientation. This
is supported by the ﬁnding that upon abolition of the formal
negative charge at position 58 in the structure of the
QacR(E58Q)-Be complex, Be moved away from a favorable
electrostatic interaction with residue E57 to a new position
in the pocket that is essentially equidistant, yet distal, 7.8
and 8.7 Å from E90 and E57, respectively. Furthermore,
mutational analyses of acidic residues involved in the charge
complementation of structurally homologous proteins rec-
ognized by the T-cell antigen CD2 suggested that this
receptor utilizes energetically neutral electrostatic interactions
to create speciﬁcity in low-energy protein-protein recogni-
tion (35). Indeed, this method of recognition has been
proposed to be highly appropriate for biological interactions
that require lower afﬁnities, uncoupling increases in speciﬁc-
ity from increases in afﬁnity. This premise may apply to the
glutamate residues of QacR and, perhaps also, to the
multidrug recognition mechanisms of other proteins, which
settle for relatively low-afﬁnity binding to their substrates
to permit recognition of a myriad of structurally dissimilar
ligands. In general support of this concept, although acidic
residues appear to provide a strong energetic contribution
to cationic ligand binding by MdfA and EmrE, it has been
suggested that the transport rate mediated by these multidrug
transporters may be inversely related to substrate binding
afﬁnity, and hence, adverse consequences, i.e., inhibition of
drug efﬂux, could arise from afﬁnities that are too
high (13, 36).
In conclusion, this study demonstrates that seemingly
unfavorable mutations of acidic residues in the QacR
multidrug binding pocket can be compensated either by an
immediate redundancy of functionally equivalent residues
or by shifts in drug orientation to permit alternative sets of
contacts, which result in near-isoenergetic and in some cases
even more favorable binding modes and further attest to the
remarkable plasticity of the QacR multidrug binding pocket.
SUPPORTING INFORMATION AVAILABLE
Results showing the determination of binding afﬁnity of
wt QacR and QacR(E58Q) for malachite green (MG) by
quenching of intrinsic tryptophan ﬂuorescence (Figure S1)
and the ITC binding isotherm for QacR(E58Q) binding to
dequalinium (Dq) (Figure S2). This material is available free
of charge via the Internet at http://pubs.acs.org.
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